Advaxis Annual Meeting Recap

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, held its annual meeting on June 1st at 10:00 am EDT at Nasdaq MarketSite in Times Square. Audio of the meeting was webcast through the company’s website.

Points discussed in the meeting:

  • Investor interest in small to mid-size biotech is higher than in large biotech/pharma
  • Advaxis stock growth has beat the Mentor Immunotherapy Index and the Nasdaq Bio index over the past 12 months
  • A dry, room temperature, stable dose of Advaxis lead immunotherapeutic candidate ADXS11-001 is currently being developed
  • Advaxis has a technology strategy to target large markets such as CIN (cervical dysplasia), breast cancer and prostate cancer
  • The company intends to expand beyond oncology and on to other types of illnesses
  • Continues to actively expand its intellectual property
  • Six (6) clinical trials in five (5) indications using three (3) constructs will be initiated over the 2010-2011 period
  • Advaxis introduced its new veterinary program which will focus on two (2) areas:
    • Canine osteosarcoma, a leading cause of death in large dogs, will use the company’s proprietary chimeric HER2 neu construct. This is closely related to osteosarcoma in human adolescents
    • The Department of Homeland Security Science and Technology Directorate and Advaxis will sign a CRADA in which an oral dosage of Listeria will be explored to treat US cattle food stock
  • This adds the DHS to other prestigious governmental bodies who are conducting research with Advaxis technology ,including NCI, Cancer Research-UK and NIH
  • Advaxis is testing a combined immunotherapy – chemotherapy regimen as part of its phase 2 study of ADXS11-001 in advanced, metastatic cervix cancer.
  • Survival in the Indian metastatic cervical cancer trial will be reported real time
  • The new Advaxis will have six (6) human trials and two (2) veterinary trials using three (3) different live attenuated Listeria vaccines
  • The financial strategy will be to minimize dilution of shareholders, maintain multiple routes to capital as a platform technology company and be a ‘disruptive technology’

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
Fax: 732-545-1084
[email protected]
or
Diana Moore, 732-545-1590
Analyst
Fax: 732-545-1084
[email protected]

KEYWORDS:   United States  North America  New Jersey  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.